MindMed reports preliminary cash ~$209.1M as of Sep 30, 2025

Definium Therapeutics, Inc.

Preliminary cash, cash equivalents and investments total approximately $209.1M as of September 30, 2025.
Data is unaudited and subject to KPMG review; may differ from final Q3 figures.
Filed a prospectus supplement and posted an updated corporate presentation on October 29, 2025.

item 2.02 item 8.01 item 9.01

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-103726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.